Scarica l'app Stockscreener
4.54
11.82%
0.48
Dopo l'orario di chiusura:
4.48
-0.06
-1.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Form 4 Myriad Genetics Inc For: 27 September By Investing.com - Investing.com Canada
Myriad Genetics, Inc. (MYGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Myriad Genetics, Inc. (MYGN) stock price, news, quote and history - Yahoo Finance Australia
3 Reasons MYGN is Risky and 1 Stock to Buy Instead - Yahoo Finance
Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments - GlobeNewswire Inc.
Myriad Genetics stock falls after guidance reset and weak Q2 figures - AD HOC NEWS
Myriad Genetics (MYGN) ex-CCO keeps stock-tied PSUs - Stock Titan
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating the Challenges in Diagnostics & Research - DirectorsTalk Interviews
Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset - Yahoo Finance
Myriad Genetics Inc. (MYGN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Form 8K Myriad Genetics Inc For: 17 September By Investing.com - Investing.com India
Myriad Genetics (NASDAQ: MYGN) Confirms 2026 Financial Outlook Amid Executive Commercial Leadership Shift - Kalkine Media
Myriad Genetics names Vishal Sikri as EVP, commercial - Medical Buyer
Myriad Genetics promotes Vishal Sikri to commercial chief By Investing.com - Investing.com South Africa
Myriad Genetics promotes Vishal Sikri to commercial chief - Investing.com
Myriad Genetics (NASDAQ: MYGN) swaps commercial chief but keeps 2026 outlook - Stock Titan
Myriad Genetics Appoints Vishal Sikri Executive Vice PresidentCommercial - Yahoo Finance
Myriad Genetics And 2 Other Penny Stocks To Consider - simplywall.st
Myriad Genetics at Wells Fargo conference: cancer focus amid pressure By Investing.com - Investing.com Canada
MYGN Maintained by UBS -- Price Target Lowered to $3.60 - GuruFocus
UBS Adjusts Price Target on Myriad Genetics to $3.60 From $6, Keeps Neutral Rating - Yahoo Finance
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN) - Yahoo Finance
Myriad Genetics Inc. (MYGN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BlackRock arm now owns more than a tenth of Myriad Genetics (NASDAQ: MYGN) - Stock Titan
Myriad Genetics Inc. (MYGN) Peer Comparison – Compare with Others - Value Research
Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter - Yahoo Finance
Why Myriad Genetics (MYGN) Stock Is Down Today - Yahoo Finance
Myriad Genetics stock downgraded at Piper Sandler (MYGN:NASDAQ) - Seeking Alpha
Myriad Genetics Stock Gets Double-Downgrade as Profitability Concerns Grow - Barron's
Myriad Genetics shares fall 7.1% after Piper Sandler downgrade - finance.yahoo.com
Why is Myriad Genetics stock tumbling today? By Investing.com - Investing.com South Africa
Why is Myriad Genetics stock tumbling today? - Investing.com
Piper Sandler cuts Myriad Genetics stock rating on profit concerns By Investing.com - Investing.com Nigeria
Piper Sandler Downgrades Myriad Genetics(MYGN.US) to Sell Rating, Cuts Target Price to $2 - Moomoo
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference - GlobeNewswire
Myriad Genetics and Moderna Shares Plummet, What You Need To Know - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect - ACCESS Newswire
Burning Rock and Myriad Announce Global Strategic Technology Lice - The National Law Review
MYGN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Myriad Genetics Inc. - accessnewswire.com
MYGN Maintained by Stephens & Co. -- Price Target Lowered to $3. - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Myriad Genetics, Inc. MYGN Stock Forecast & Price Target - Yahoo Finance
Marquis Who's Who Honors Ben Wheeler for Expertise in Finance and Healthcare - 24-7 Press Release Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Myriad Genetics (MYGN): Glenview Capital and Larry Robbins report exit from stake - Stock Titan
Myriad Genetics (MYGN): Vestal Point Capital discloses 6.1% stake in 13G filing - Stock Titan
Myriad Genetics Faces Multiple Investor Investigations - stl.news
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN - MarketBeat
3 Healthcare Stocks with Open Questions - Yahoo Finance
0.97%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):